> Back to EJC

Recent editions

  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.
  • November 2015
    Caroline Robert on new developments in immunotherapy.
  • October 2015
    Milena Sant on the latest results from the EUROCARE study.
  • September 2015
    The science behind the IARC code that could reduce cancer in Europe.
  • July/August 2015
    Thomas Helleday on an exciting new class of drug, MTH1 inhibitors.
  • June 2015
    Lesley Seymour and Jan Bogaerts on the future of RECIST.
  • May 2015
    Paul Workman on strategies for overcoming resistance to new drugs.
  • April 2015
    Highlights from the TAT Congress in Paris.
  • March 2015
    Christopher Wild on the exposome, a measure of environmental exposure.
  • February 2015
    Mathematicians are developing a blood flow model for metastasis.
  • January 2015
    René Bernards on discovering effective drug combinations.

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – May 2013

Loading EJC News Focus video

Highlights of 2nd ESTRO Forum

By the year 2020, it is estimated that for every tumour, data will be available on 10,000 markers related to survival. How are clinicians to make sense – and practical use – of it all?

According to ESTRO President, Vincenzo Valentini, a good way to start might be to involve radiation oncologists who already have expertise in complex imaging and dose-planning models. The decision models of the future will become even more sophisticated, he says, able to codify quality of life so that the needs of individual patients can be met.

This was just one of the themes of the 2nd ESTRO Forum (Geneva; 19-23 April 2013). Others included the combination of radiation therapy and drugs; and the use of a single shot of radiotherapy to control pain. Here Vincenzo Valentini discusses the highlights of the forum with Helen Saul.